EDGAR Filing Documents for 0001193125-23-103622

Form 8-K - Current report:

SEC Accession No. 0001193125-23-103622

Filing Date

2023-04-17

Accepted

2023-04-17 16:17:56

Documents

Period of Report

2023-04-12

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	d487416d8k.htm iXBRL	8-K	43939
2	EX-4.1	d487416dex41.htm	EX-4.1	618619
3	EX-99.1	d487416dex991.htm	EX-99.1	11745
4	EX-99.2	d487416dex992.htm	EX-99.2	12760
8	GRAPHIC	g487416g0415033754715.jpg	GRAPHIC	3666
9	GRAPHIC	g487416g0415033835182.jpg	GRAPHIC	3773
	Complete submission text file	0001193125-23-103622.txt		957428

Data Files

Seq	Description	Document	Type	Size
5	XBRL TAXONOMY EXTENSION SCHEMA	mirm-20230412.xsd	EX-101.SCH	2851
6	XBRL TAXONOMY EXTENSION LABEL LINKBASE	mirm-20230412_lab.xml	EX-101.LAB	18738
7	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	mirm-20230412_pre.xml	EX-101.PRE	11708
11	EXTRACTED XBRL INSTANCE DOCUMENT	d487416d8k_htm.xml	XML	3470

Mailing Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404

Business Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404 650-667-4085

Mirum Pharmaceuticals, Inc. (Filer) CIK: 0001759425 (see all company filings)